SCHMC
Login
순천향대학교 부속 천안병원
검색
커뮤니티
제목
저자
키워드
발행일
SCHMC Repository
진료부
종양혈액내과
2. Conference Papers
28
browse
제목
저자
키워드
발행일
이 컬렉션을 구독하여 매일 이메일로 알림을 받겠습니다.
21
Conference
Modified FOLFIRINOX (5-FU/LV, irinotecan and oxaliplatin) as second-line chemotherapy for gemcitabine-resistant or -refractory advanced pancreatic cancer
이상철
;
이규택
;
배상병
;
et al
2015
22
Conference
In vitro functional study of novel oncogene serine protease 33 (PRSS33) and the clinical significance of PRSS33 expression in colorectal cancer patients
김한조
;
안태성
;
전섭
;
et al
2016
23
Conference
Defensin-alpha 6 (DEFA6) as a protumorigenic function in vitro and prognostic marker in colorectal cancer
김한조
;
안태성
;
전섭
;
et al
2016
24
Conference
Sulindac enhances arsenic trioxide mediated apoptosis of HCT116 colon cancer cell line by inhibition of nuclear factor-kappa B
배상병
;
이규택
2006
25
Conference
Three-dimensional high-throughput drug screening for bladder cancer
이상철
2019
26
Conference
In vitro functional study of Ang 2 in colorectal cancer cell line and the significance of Ang 2 expression in colorectal cancer patients
백무준
;
김창진
;
김한조
;
et al
2014
27
Conference
Overexpression of nuclear karyopherin alpha2 correlates with poor prognosis in patients with colorectal cancer
백무준
;
김창진
;
김한조
;
et al
2014
28
Conference
Relationship between RAS, BRAF, PIK3CA and location of primary tumor in urothelial carcinoma
이상철
2019
<<
<
1
2
Recent Submissions
A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial
Nationwide real-world practice pattern and clinical data of palbociclib in patients with HR(+), HER2(-) metastatic breast cancer (KCSG BR21-15)
Hidden advertisements included in cancer information posts: Insights from social listening
Comprehensive analysis of mutation and expression based pathways in head and neck squamous cell carcinoma
Attenuated FOLFIRINOX (5-FU/LV, irinotecan and oxaliplatin) as second-line chemotherapy for the Koreans (Asian population) with gemcitabine-resistant or –refractory advanced pancreatic cancer
Anonymous
Login
커뮤니티
제목
저자
키워드
발행일
Guide